Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    14695413 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Enrolling by invitation Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: GM-CSF [Leukine (Sargramostim)];   Procedure: WLL
2 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan
3 Recruiting A National Registry For Pulmonary Alveolar Proteinosis
Condition: Pulmonary Alveolar Proteinosis
Intervention:

Study has passed its completion date and status has not been verified in more than two years.